Filtered By:
Drug: Glyburide

This page shows you your search results in order of date.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide
Cell Rep Med. 2022 Jun 9:100654. doi: 10.1016/j.xcrm.2022.100654. Online ahead of print.ABSTRACTBrain edema after a large stroke causes significant morbidity and mortality. Here, we seek to identify pharmacodynamic markers of edema that are modified by intravenous (i.v.) glibenclamide (glyburide; BIIB093) treatment. Using metabolomic profiling of 399 plasma samples from patients enrolled in the phase 2 Glyburide Advantage in Malignant Edema and Stroke (GAMES)-RP trial, 152 analytes are measured using liquid chromatography-tandem mass spectrometry. Associations with midline shift (MLS) and the matrix metalloproteinase-9 (MM...
Source: Cancer Control - June 14, 2022 Category: Cancer & Oncology Authors: Hannah J Irvine Animesh Acharjee Zoe Wolcott Zsuzsanna Ament H E Hinson Bradley J Molyneaux J Marc Simard Kevin N Sheth W Taylor Kimberly Source Type: research

Brain Targeting, Antioxidant Polymeric Nanoparticles for Stroke Drug Delivery and Therapy
This study develops nanoparticles (NPs) consisting of a reactive oxygen species (ROS)-reactive polymer and further engineers them for targeted drug delivery to the ischemic brain through ligand-mediated interaction and thrombin-triggered shrinkability. It is demonstrated that the resulting NPs can efficiently deliver glyburide to the brain for effective stroke treatment. AbstractIschemic stroke is a leading cause of death and disability and remains without effective treatment options. Improved treatment of stroke requires efficient delivery of multimodal therapy to ischemic brain tissue with high specificity. Here, this ar...
Source: Small - March 20, 2022 Category: Nanotechnology Authors: Haoan Wu, Bin Peng, Farrah S. Mohammed, Xingchun Gao, Zhenpeng Qin, Kevin N. Sheth, Jiangbing Zhou, Zhaozhong Jiang Tags: Research Article Source Type: research

BIIB093 (intravenous glibenclamide) for the prevention of severe cerebral edema
CONCLUSION: Studies analyzing the GAMES-Pilot and GAMES-PR trials suggest that glibenclamide has a moderate, however, measurable effect on intermediate biomarkers and clinical endpoints. Meaningful conclusions are limited by the small sample size of patients studied.PMID:33767884 | PMC:PMC7982107 | DOI:10.25259/SNI_933_2020
Source: Surgical Neurology International - March 26, 2021 Category: Neurosurgery Authors: Daniel W Griepp Jason Lee Christina M Moawad Cyrus Davati Juliana Runnels Brian Fiani Source Type: research